Amphastar Pharmaceuticals Total Current Assets 2012-2024 | AMPH

Amphastar Pharmaceuticals total current assets from 2012 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Amphastar Pharmaceuticals Annual Total Current Assets
(Millions of US $)
2023 $490
2022 $378
2021 $318
2020 $280
2019 $255
2018 $220
2017 $188
2016 $184
2015 $176
2014 $198
2013 $173
2012 $166
2011 $
2009 $44
Amphastar Pharmaceuticals Quarterly Total Current Assets
(Millions of US $)
2024-09-30 $546
2024-06-30 $483
2024-03-31 $555
2023-12-31 $490
2023-09-30 $543
2023-06-30 $385
2023-03-31 $408
2022-12-31 $378
2022-09-30 $384
2022-06-30 $377
2022-03-31 $364
2021-12-31 $318
2021-09-30 $304
2021-06-30 $311
2021-03-31 $300
2020-12-31 $280
2020-09-30 $277
2020-06-30 $267
2020-03-31 $247
2019-12-31 $255
2019-09-30 $269
2019-06-30 $284
2019-03-31 $230
2018-12-31 $220
2018-09-30 $195
2018-06-30 $170
2018-03-31 $174
2017-12-31 $188
2017-09-30 $176
2017-06-30 $194
2017-03-31 $191
2016-12-31 $184
2016-09-30 $190
2016-06-30 $181
2016-03-31 $173
2015-12-31 $176
2015-09-30 $199
2015-06-30 $204
2015-03-31 $203
2014-12-31 $198
2014-09-30 $215
2014-06-30 $214
2014-03-31 $177
2013-12-31 $173
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $166
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.335B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00